Dr. Muehlschlegel completed clinical training in neurology, vascular neurology and neurocritical care, and is triple board certified in these subspecialties. She has obtained additional research training through the completion of the Harvard School of Public Health Summer Program for Clinical Effectiveness and Masters of Public Health Program, with a focus in Clinical Effectiveness. During fellowship, under the mentorship of neurointensivist, translational scientist and director of neurocritical care at Massachusetts General Hospital (MGH), John R. Sims, MD, she became initially engaged in cerebral vasoconstriction syndromes and studying dantrolene as a novel means for prevention and treatment of cerebral vasospasm after subarachnoid hemorrhage, as well as in the reversible vasoconstriction syndrome “Call-Fleming-Syndrome”. Her work was funded by the American Heart Association Scientist Development Grant, and the 2010 Worcester Research Foundation, and results of her investigator initiated feasibility trial of Dantrolene after subarachnoid hemorrhage is in prepartion for publication. Supported by the University of Massachussetts Medical School (UMASS) Faculty Scholar award (to support women in research during times of increased family responsibilities), she turned to her passion: improving the outcome prognostication of moderate-severe traumatic brain injury admitted to the neurointensive care unit. Mentored by senior epidemiologist Robert Goldberg, PhD, she is studying the longitudinal course of critically ill TBI patients, creating new prediction tools, and demonstrating the variability of outcome prognostication by clinicians. She is currently interested in developing shared decision making tools, which may ultimately limit uninformed withdrawal of care or futile prolongation of life decisions by families and physician biases (http://informedmedicaldecisions.org/what-is-shared-decision-making). This work is in line with the Patient Protection and Affordable Care Act of 2010 which supports a national shared decision making program http://www.nejm.org/doi/full/10.1056/NEJMp1209500.
Dr. Muehlschlegel and her colleague Dr. Carandang are the co-founders of the New England Neurocritical Care Research Consortium (NENCC), a regional consortium consisting of MGH, UMASS, BWH, Boston Medical Center, Yale, Baystate Medical Center and Rhode Island Hospital, with the goal of facilitating collaborative multi-center research in neurocritical care.
Dr. Muehlschlegel is the co-chair of the Neurocritical Care Society Website Committee (www.neurocriticalcare.org), and member of the newsletter editorial board. Since 2013, she has been an elected member of the Board of Directors of the Neurocritical Care Society, and is currently serving a 4-year term. The Neurocritical Care Society is the largest international multidisciplinary neurocritical care professional society dedicated to improve the health care and outcomes of patients with life-threatening neurological illnesses by promoting quality patient care, professional collaboration, research, training and advocacy.
Dr. Muehlschlegel is a well-recognized teacher. She has been was actively involved in daily teaching of medical students and residents in neurology and other disciplines since residency. As a chief resident she organized bi-weekly neurology board review sessions, as well as other regular teaching conferences and journal clubs. As a fellow, her teaching efforts continued, and involved daily resident education sessions during or after rounds on acute stroke and neurointensive care issues. She initiated a combined lecture series of surgical ICU and neuro-ICU fellows. She was actively involved as a lecturer at the ACLS course for health care providers at MGH. As a UMASS faculty member, Dr. Muehlschlegel is currently responsible for the supervision of surgical critical care fellows, residents, medical students and mid-level providers (PA/ARNP) in the trauma and neuro-ICU. She established a regular bi-weekly teaching lecture series for the mid-level providers specialized in neuro-ICU. She gives lectures regularly to neurology, emergency medicine, anesthesia and surgery residents. When on service in the ICU, she provides teaching to the ICU team with all its members during the daily SICU morning lectures. She teaches all ICU procedures as well as all clinical aspects of neurocritical care. She has been co-director of the UMASS Department of Neurology/Neuroscience Journal Club since 2008.
As a neurointensivist, Dr. Muehlschlegel is one of only approximately 500 U.S. board certified subspecialists in this field. She is involved in the direct care of critically ill neurology, neurosurgery and trauma patients. She managed all neuroICU and general surgical ICU problems, including but not limited to ventilators, hemodynamics, sepsis, nutrition, electrolyte imbalances, acid-base disorders, infections, and ventriculostomies. She is known to communicate very effectively and empathetically with family members and establishes great rapport with patients and affected families.
Post-Graduate Medical and Research Training:
2002-2006 -- Neurology Residency, University of Florida
2005-2006 -- Chief Resident (Neurology), University of Florida
2006-2008 -- Neurocritical Care and Vascular Neurology Fellowship, Massachusetts General Hospital and Brigham & Women's Hospital, Harvard Medical School
2007-2010 -- Masters of Public Health (Clinical Effectiveness), Harvard School of Public Health